Zurich-Roche is looking for another place to test the pill to fight COVID-19 after the sharp drop in the number of cases in the UK has made it difficult to find enough patients for the study there. The Swiss pharmaceutical company said Wednesday.
Atea Pharmaceuticals, a Roche and Boston-based partner, said the AT-527 pill provides antiviral therapy to treat patients with COVID-19, more than other future therapies such as antibody cocktails and Gilead Sciences’ remdesivir. We hope it will be easier and cheaper to administer.
In an interview with Swiss media in early March, Roche Chairman Christoph Franz will be able to provide a compelling outlook for data on AT-527 “within the next few weeks” and fight pandemics with pills by the end of the year. I was dreaming about.
However, the UK, which succeeded in reducing the number of cases through a rapid vaccination program and a strict blockade, meant that it took longer than expected to collect data from the trials there, Roche’s pharmaceutical division said. Said Bill Anderson, who is responsible for the.
“We just don’t have enough patients to enroll at the speed we wanted,” Anderson said in a conference call.
“This is one of the challenges since the pandemic started. By the time we set up a site with a lot of COVIDs and are ready to register, the pandemic has moved to another location and is doing some sort of tracking. It.”
He did not identify other places where Roche could set up the exam.
Atea receives a $ 350 million down payment from Roche, which could lead to future milestone payments and royalties. Athea, along with Roche, is trying the drug in patients with mild to moderate COVID-19. We are also conducting individual trials at hospitals with more severely ill patients.